Itchy

Keep Your Pets Safe This Holiday Season

Retrieved on: 
Thursday, December 22, 2022
Wind, Cat, Levis De-Icer, Propylene glycol, Lake, Ice, Car, Depression, Tail, Skin, PETS, Temperature, Frostbite, Vomiting, Abdomen, Dog, Animal, Itchy, River, Walking, Weather, Snow, Reindeer, Fish flake, Ethylene glycol, ID, Christmas, Hypothermia, Fur clothing, Mineral oil, Petroleum jelly

Washington, D.C., Dec. 22, 2022 (GLOBE NEWSWIRE) -- The holiday season is upon us, which marks the official start of winter in the United States.

Key Points: 
  • Washington, D.C., Dec. 22, 2022 (GLOBE NEWSWIRE) -- The holiday season is upon us, which marks the official start of winter in the United States.
  • The Christmas season is all about giving, and you’ll need to remember to give your pets the best possible care during the potentially dangerous winter months ahead.
  • Exposure to winter’s dry, cold air and chilly rain, sleet and snow can cause chapped paws and itchy, flaking skin for your pets.
  • Below are some simple tips to ensure a humane winter and help you prioritize your pets’ safety:
    Plan ahead and pay attention to cold-weather warnings.

The Worldwide Allergic Conjunctivitis Industry is Estimated to Reach $2.9 Billion by 2031 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 4, 2023
Health, Optical, Conjunctivitis, Allergic conjunctivitis, Allergy, Conjunctiva, Allergen, Market share, Common, Allergic rhinitis, Eyelid, Urbanization, Porter's five forces analysis, Pollen, Itchy, Gonorrhea, National Centre for Cold-chain Development, Semen, Growth, Patient, Benchmarking, Vertically transmitted infection, Asthma, Distribution, Spore, Eye, STI, Asthma and Allergy Foundation of America, Prevalence, Chlamydia, Cosmetics, Marketing

The global allergic conjunctivitis market was valued at $1,937.99 million in 2021, and is estimated to reach $2,954.2 million by 2031, growing at a CAGR of 4.28% from 2022 to 2031.

Key Points: 
  • The global allergic conjunctivitis market was valued at $1,937.99 million in 2021, and is estimated to reach $2,954.2 million by 2031, growing at a CAGR of 4.28% from 2022 to 2031.
  • An allergic reaction to things such as pollen, mold, or spores can result in an eye inflammation known as allergic conjunctivitis.
  • The major factors that drive the growth of the allergic conjunctivitis market are increase in patient population suffering from ocular allergies.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the allergic conjunctivitis market analysis from 2021 to 2031 to identify the prevailing allergic conjunctivitis market opportunities.

Aditxt Forms Adimune, Inc. as a Wholly Owned Subsidiary with a Focus on Immune Modulation Therapies and Appoints Dr. Friedrich Kapp, Former President of the Therapeutic Business Unit at Schering AG, as its Chairman and CEO

Retrieved on: 
Tuesday, January 3, 2023
Health, Diabetes, Health Technology, Clinical Trials, Pharmaceutical, Biotechnology, Acceleration, Scaly, GMP, Skin, Psoriasis, Immune tolerance, Inflammation, Schering AG, Itchy, Joint Medical Service (Germany), Patient, CTA, Degenerative disease, Small Business Saturday, Immune system, Pharmaceutical industry, Vaccine

The CTA application will request approval for Adimune™ to conduct the first-in-human study in psoriasis patients, beginning in the second half of 2023.

Key Points: 
  • The CTA application will request approval for Adimune™ to conduct the first-in-human study in psoriasis patients, beginning in the second half of 2023.
  • Joachim-Friedrich Kapp, M.D., Ph.D., a 30-year veteran of the pharmaceutical industry and former president of the Therapeutics Business Unit at the multinational pharmaceutical company Schering AG, will serve as CEO of Adimune™ and chairman of the board.
  • Among his responsibilities as CEO of Adimune™, Dr. Kapp will be tasked with leading and developing the ADI™ immune modulation technology toward clinical trials.
  • Adimune’s™ product aims to prevent immune attacks by restoring immune tolerance and addressing the root cause of inflammation in skin.

Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome

Retrieved on: 
Tuesday, December 13, 2022
Asthma, Scaly, Quality of life, Clinical trial, Itchy, Dermatitis, Food, FDA, Safety, Dehydration, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Epidermolysis bullosa, Skin, Hair, SPINK5, Infection, Risk, Netherton syndrome, Attention deficit hyperactivity disorder predominantly inattentive, Mutation, IND, Standard of care, Peeling skin syndrome, Patient, Pharmaceutical industry, Scleroderma, Netherton

ASHBURN, Va., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, announces that the first patient has been dosed in its ongoing clinical trial evaluating the safety and efficacy of QRX003 as a treatment for Netherton Syndrome.

Key Points: 
  • This second study, which has now been cleared by the FDA to initiate clinical testing, is an open-label, non-placebo controlled trial that will evaluate 10 Netherton patients over a twelve week period.
  • The dosing of our first patient and the clearance of our second study are big steps forward for Quoin and, hopefully, for the community in general.
  • Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases.
  • Netherton Syndrome is a rare and sometimes fatal skin disease for which there is no approved treatment, and no cure.

Flaviar Thanks Santa Clauses This Holiday Season

Retrieved on: 
Thursday, December 8, 2022
Itchy, MS, SD, DE, Santa Claus, OK, Calendar, Confusion, HI, Amusement park

NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Today, Flaviar announced a holiday initiative dedicated to celebrating all the real Santa Clauses of the Holiday season. Flaviar – America’s #1 luxury spirits membership club – has long prided itself on making it easy to be a great gift-giver during the holiday season. This year, Flaviar is launching a “Flaviar Thanks Santa” contest that will give gifts to the everyday people who work or volunteer their time to be Santa Claus and make our spirits bright.This campaign invites anyone who dresses up or plays Santa Claus (or Mrs. Claus), professionally or not, the opportunity to share their favorite story for a chance to win one of a hundred all-inclusive Flaviar Club memberships worth over $350. The all-inclusive membership is a year-long tasting journey, coming with eight free products from the Flaviar lineup, free shipping on all orders over $60, early access to exclusive bottles, and access to virtual and in-person events. “At Flaviar, we’ve often joked in advertisements that Santa hates us because we make it so easy to be a great gift giver,” says Flaviar CMO Todd Bellucci. “So this year, we wanted to tip our cap to all the people who decide to put on that hot, itchy costume to bring a smile to people’s faces. These are real people behind the beard, and we think they deserve a gift.”

Key Points: 
  • Flaviar, Inc. surprised a party of Santa Clauses with free, one-year Flaviar memberships to kick off their Flaviar Thanks Santa holiday contest campaign
    NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Today, Flaviar announced a holiday initiative dedicated to celebrating all the real Santa Clauses of the Holiday season.
  • Flaviar – America’s #1 luxury spirits membership club – has long prided itself on making it easy to be a great gift-giver during the holiday season.
  • This year, Flaviar is launching a “Flaviar Thanks Santa” contest that will give gifts to the everyday people who work or volunteer their time to be Santa Claus and make our spirits bright.
  • These are real people behind the beard, and we think they deserve a gift.”
    To launch this campaign, Flaviar hired ten Santa Clauses, under the guise of providing entertainment for Flaviar's company Holiday party.

Escient Pharmaceuticals Announces Oral Presentation of Data Highlighting the Preclinical Development of EP262 at the 6th GA2LEN Global Urticaria Forum

Retrieved on: 
Wednesday, December 7, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Peptide, Therapy, Escient, Hives, CSU, Ligand, Itchy, Cytokine, Cold urticaria, Doctor of Philosophy, Skin, B cell, Patient, Translation (biology), Angioedema, Histamine, Chemokine, Pain, Sleep, MRGPRX4, Cholestatic pruritus, MRGPRX2, Tissue, Drug discovery, Atopic dermatitis, Pharmaceutical industry, Vaccine

Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the presentation of preclinical data related to the companys EP262 development program at the 6th GA2LEN Global Urticaria Forum being held in Berlin, Germany, December 7-8, 2022.

Key Points: 
  • Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the presentation of preclinical data related to the companys EP262 development program at the 6th GA2LEN Global Urticaria Forum being held in Berlin, Germany, December 7-8, 2022.
  • EP262, a potent, highly selective antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), represents a novel, targeted approach to the treatment of mast cell-mediated disorders.
  • In chronic inducible urticaria (CIndU), hives are induced by specific triggers such as cold exposure (cold urticaria) or touch (symptomatic dermographism), among others.
  • Escient Pharmaceuticals is a clinical-stage company focused on developing novel therapeutics to address a broad range of neurosensory-inflammatory disorders.

Hornitos® Tequila Turns Disastrous White Elephant Gifts into "Dough" this Holiday Season

Retrieved on: 
Thursday, December 8, 2022
Plata, Itchy, White elephant, Cry of Dolores, NO, History, Holiday, Senior, Multimedia, Risk, Online shopping, Liquor, Sweepstake

NEW YORK, Dec. 8, 2022 /PRNewswire/ -- 'Tis the season of giving and re-gifting! If you're lucky enough to be on the invitee list of a white elephant party, you run the risk of leaving with a completely useless gift (we've all been there!).

Key Points: 
  • This holiday season, Hornitos Tequila is here to save the day by allowing folks to exchange those itchy tube socks and creepy cat calendars for something a bit more green.
  • To help spread more cheer, Hornitos teamed up with the hilarious TonyTalks to serve as the honorary virtual "shopkeeper," helping turn this year's white elephant disasters into dough.
  • To learn more about Hornitos Tequila and its shot-taking brand history, visit www.hornitostequila.com or follow along with Hornitos Tequila on Instagram , Twitter and Facebook .
  • Hornitos' portfolio of premium tequilas includes Hornitos Plata Tequila, Hornitos Reposado Tequila, Hornitos Aejo Tequila, Hornitos Cristalino Tequila, Hornitos Black Barrel Tequila HornitosTequila Seltzer and a line of ready-to-serve premixed margaritas.

Vegan Soaps Global Market Report 2022: Benefits of Using Vegan Soaps Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 29, 2022
Organic Food, Cosmetics, Retail, Department Stores, Supermarket, Specialty, Online, Growth, Skin, Vegetable, Itchy, Hand, Distribution, Seed, Plant, Urbanization, Chocolate, Calendula, Psoriasis, Olive oil, Dermatitis, Soap, Online shopping, Liquid

The global vegan soaps market is anticipated to witness significant growth over the forecast period, 2023-2027.

Key Points: 
  • The global vegan soaps market is anticipated to witness significant growth over the forecast period, 2023-2027.
  • There are several benefits of using vegan soaps, and the market players are adopting attractive marketing strategies to spread information about the advantages of using vegan soap among consumers.
  • The advantages of using vegan soaps are expected to boost the global vegan soaps market growth over the next years.
  • They can read the ingredients and benefits of using vegan soaps and then make informed decisions.

Dermavant Launches First Commercial for VTAMA® (tapinarof) cream, 1% as Part of a National, Multimedia Campaign for Adults with Plaque Psoriasis

Retrieved on: 
Tuesday, November 22, 2022
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Itch, Inflammatory bowel disease, Marketing, Cell, Groin, Neck, Irritation, Multimedia, Headache, Body surface area, Empathy, Face, Journal of Dermatological Treatment, Risk, Human, Aryl hydrocarbon receptor, Itchy, Folliculitis, Obesity, Research, Depression, Progress, Pain, Hypertension, Smoking, NPA, Incidence, Stinger, FDA, Psoriasis, Common, Atopic dermatitis, National Psoriasis Foundation, Swelling, Rash, Genetics, Roivant Sciences, Therapy, Diabetes, Dermatology, Food, Veni, vidi, vici, Calendar, Skin, Injection, Nose, Prescription, Weather, Inflammation, Gesellschaft mit beschränkter Haftung, Patient, Pharmaceutical industry, Cosmetics, Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology

Many have been waiting a long time for a different plaque psoriasis treatment like VTAMA cream.

Key Points: 
  • Many have been waiting a long time for a different plaque psoriasis treatment like VTAMA cream.
  • The commercial gives topical plaque psoriasis patients aka the silent majority a voice, empowering them to demand more from their topical plaque psoriasis treatment and truly feel heard.
  • Indication: VTAMA (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.
  • Plaque psoriasis, also called psoriasis vulgaris, is the most common form and affects about 80 to 90% of people with psoriasis.

NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin Returns to the QVC® Network With DERMAdoctor’s Eczema Balm

Retrieved on: 
Thursday, November 17, 2022
Women, Biotechnology, Family, Health, Cosmetics, Consumer, Pharmaceutical, Retail, Optical, Medical News Schering, Skin, Linoleic acid, Medical News Today, Form, NovaBay Pharmaceuticals, Itchy, NYSE, Security (finance), Asthma, Red, Milgram & Company Ltd., QVC, Atopic dermatitis, Register, MD, Ceramide, Dermatitis, Blepharitis, Publication, Cosmetics, Amazon

(NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Chief Product Officer Audrey Kunin, MD will return for her fourth appearance this year on the QVC network.

Key Points: 
  • (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Chief Product Officer Audrey Kunin, MD will return for her fourth appearance this year on the QVC network.
  • I am excited to share our moisture-rich, problem-solving Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm on QVC just in time for holiday giving, said Dr. Kunin.
  • Dry indoor air during the winter months can exacerbate parched, eczema-prone skin, leading to itching, redness and discomfort.
  • Dr. Kunin is a board-certified dermatologist, author, clinician, educator, television personality and recognized trailblazer in the skincare industry.